Search: onr:"swepub:oai:lup.lub.lu.se:1af7bc56-69d0-40ce-8230-5e548cd04751" >
High-Target Hemodia...
-
Vernooij, Robin W.M.University Medical Center Utrecht
(author)
High-Target Hemodiafiltration Convective Dose Achieved in Most Patients in a 6-Month Intermediary Analysis of the CONVINCE Randomized Controlled Trial
- Article/chapterEnglish2023
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:1af7bc56-69d0-40ce-8230-5e548cd04751
-
https://lup.lub.lu.se/record/1af7bc56-69d0-40ce-8230-5e548cd04751URI
-
https://doi.org/10.1016/j.ekir.2023.08.004DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Introduction: High convection volumes in hemodiafiltration (HDF) result in improved survival; however, it remains unclear whether it is achievable in all patients. Methods: CONVINCE, a randomized controlled trial, randomized patients with end-stage kidney disease 1:1 to high-dose HDF versus high-flux hemodialysis (HD) continuation. We evaluated the proportion of patients achieving high-dose HDF target: convection volume per visit of ≥23 l (range ±1 l) at baseline, month 3, and month 6. We compared baseline characteristics in the following 2 ways: (i) patients on target for all 3 visits versus patients who missed target on ≥1 visits and (ii) patients on target for all 3 visits or missing it once versus patients who missed target on ≥2 visits. Results: A total of 653 patients were randomized to HDF. Their mean age was 62.2 (SD 13.5) years, 36% were female, 81% had fistula vascular access, and 33% had diabetes. Across the 3 visits, 75 patients (11%), 27 patients (4%), and 11 patients (2%) missed the convection volume target once, twice, and thrice, respectively. Apart from diabetes, there were no apparent differences in patient characteristics between patients who always achieved the high-dose target (83%) and those who missed the target either once or more (17%) or twice or more (6%). Conclusion: Achieving high-dose HDF is feasible for nearly all patients in CONVINCE and could be maintained during the 6-month follow-up period. Apart from diabetes, there were no other indications for confounding by indication on multivariable analyses that may explain the potential survival advantage for patients receiving high-dose HDF.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Hockham, C.Imperial College London
(author)
-
Barth, C.
(author)
-
Canaud, B.University of Montpellier
(author)
-
Cromm, K.Fresenius Medical Care Deutschland GmbH
(author)
-
Davenport, A.University College London
(author)
-
Hegbrant, J.Lund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)jo0134he
(author)
-
Rose, M.Berlin Institute of Health (BIH),Charité - University Medicine Berlin
(author)
-
Strippoli, G. F.M.University of Sydney,University of Bari Aldo Moro
(author)
-
Török, M.
(author)
-
Woodward, M.Imperial College London,University of New South Wales
(author)
-
Bots, M. L.University Medical Center Utrecht
(author)
-
Blankestijn, P. J.University Medical Center Utrecht
(author)
-
University Medical Center UtrechtImperial College London
(creator_code:org_t)
Related titles
-
In:Kidney International Reports8:11, s. 2276-22832468-0249
Internet link
Find in a library
To the university's database
- By the author/editor
-
Vernooij, Robin ...
-
Hockham, C.
-
Barth, C.
-
Canaud, B.
-
Cromm, K.
-
Davenport, A.
-
show more...
-
Hegbrant, J.
-
Rose, M.
-
Strippoli, G. F. ...
-
Török, M.
-
Woodward, M.
-
Bots, M. L.
-
Blankestijn, P. ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Urology and Neph ...
- Articles in the publication
-
Kidney Internati ...
- By the university
-
Lund University